1. Home
  2. HHH vs NAMS Comparison

HHH vs NAMS Comparison

Compare HHH & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Howard Hughes Holdings Inc.

HHH

Howard Hughes Holdings Inc.

HOLD

Current Price

$64.82

Market Cap

3.8B

Sector

Real Estate

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$28.54

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HHH
NAMS
Founded
2010
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.7B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
HHH
NAMS
Price
$64.82
$28.54
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$90.00
$46.75
AVG Volume (30 Days)
328.7K
904.9K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$1,474,892,000.00
N/A
Revenue This Year
$14.04
$17.96
Revenue Next Year
N/A
$540.65
P/E Ratio
$472.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$61.01
$21.14
52 Week High
$91.07
$42.21

Technical Indicators

Market Signals
Indicator
HHH
NAMS
Relative Strength Index (RSI) 38.56 35.54
Support Level $61.79 N/A
Resistance Level $68.25 $37.29
Average True Range (ATR) 1.64 1.84
MACD -0.74 -0.56
Stochastic Oscillator 9.91 5.38

Price Performance

Historical Comparison
HHH
NAMS

About HHH Howard Hughes Holdings Inc.

Howard Hughes Holdings Inc, through its subsidiary, operates a large-scale, mixed-use real estate platform focused on the development of master planned communities (MPCs), the investment in strategic real estate development opportunities, and the ownership and operation of income-producing properties. The group operates through three reportable business segments: Operating Assets, MPCs, and Strategic Developments. Maximum revenue is generated from the MPC segment, which consists of the development and sale of land in large-scale, long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. Revenues are mainly generated through the sale of residential and commercial land to homebuilders and developers.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: